Rituxan

AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
S&P Global
AbbVie
Roche
Humira
Rituxan
Herceptin
Avastin
Flag link:
Pfizer’s latest copycat could put the squeeze on Roche — again
Pfizer’s latest copycat could put the squeeze on Roche — again
Endpoints
Pfizer
Roche
biosimilars
Rituxan
PF-05280586
Flag link:
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Fierce Pharma
Roche
Pharma CEOs
Severin Schwan
biosimilars
Herceptin
Rituxan
Avastin
Flag link:
Roche's Fight With Pfizer May Be Just The Beginning
Roche's Fight With Pfizer May Be Just The Beginning
Forbes
Roche
Pfizer
Herceptin
biosimilars
cancer
Avastin
Rituxan
Flag link:
Good quarter for Roche, but competition by biosimilars concerns investors
Good quarter for Roche, but competition by biosimilars concerns investors
GoinPharma
Roche
earnings
biosimilars
Rituxan
Flag link:
Roche feeling first effects of biosimilar Rituxan
Roche feeling first effects of biosimilar Rituxan
Biopharma Dive
Roche
biosimilars
Rituxan
earnings
Flag link:
AbbVie, Roche to seek broader market for leukemia drug after trial success
AbbVie, Roche to seek broader market for leukemia drug after trial success
BioPharma Dive
AbbVie
Roche
clinical trials
Venclexta
Rituxan
chronic lymphocytic leukemia
Flag link:
Poor test results for Roche cloud growth prospects
Poor test results for Roche cloud growth prospects
Yahoo/Reuters
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link:
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
Flag link:
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Flag link:
Novartis scores second biosimilar approval in two weeks
Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Novartis
biosimilars
Enbrel
Europe
Sandoz
Erelzi
Roche
Rituxan
Flag link:
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Endpoints
Novartis
biosimilars
Rituxan
Roche
Sandoz
Flag link:
Amid sales growth, Roche plans defense from biosimilar threats
Amid sales growth, Roche plans defense from biosimilar threats
BioPharma Dive
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link:
The 19 Best-Selling Prescription Drugs of All-Time
The 19 Best-Selling Prescription Drugs of All-Time
Motley Fool
Lipitor
Humira
Seretide
Remicade
Plavix
Enbrel
Rituxan
Herceptin
Avastin
Nexium
Zyprexa
Flag link:
Teva ponies up $160M-plus for marketing rights to Celltrion's Rituxan, Herceptin biosims
Teva ponies up $160M-plus for marketing rights to Celltrion's Rituxan, Herceptin biosims
Fierce Pharma
Teva Pharmaceutical
Celltrion
Rituxan
Herceptin
biosimilars
Flag link:
Roche's Hematology Franchise Almost 100% Protected From Biosimilars
Roche's Hematology Franchise Almost 100% Protected From Biosimilars
Seeking Alpha
Roche
hematology
biosimilars
Gazyva
Rituxan
Flag link:
Roche's pharma chief sees no 'short term' pricing pressure on its cancer blockbusters
Roche's pharma chief sees no 'short term' pricing pressure on its cancer blockbusters
Fierce Pharma
Roche
drug pricing
Rituxan
Avastin
Herceptin
Flag link:
Roche readies new drugs in two-year window before copycats hit
Roche readies new drugs in two-year window before copycats hit
Yahoo/Reuters
Roche
biosimilars
Herceptin
Rituxan
Flag link:
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Fierce Pharma Marketing
biosimilars
AbbVie
Roche
Amgen
Rituxan
Herceptin
Avastin
Neupogen
Neulasta
Epogen
Humira
Perjeta
Gazyva
Flag link:
Biogen Goes Generic
Biogen Goes Generic
Investopedia
Biogen
generics
Rituxan
anti-TNF
SB4
biosimilars
Remicade
SB2
Enbrel
Flag link:

Pages